-
Je něco špatně v tomto záznamu ?
Second-generation piperazine derivatives as promising radiation countermeasures
V. Chmil, N. Živná, M. Milanová, A. Filipová, J. Pejchal, L. Prchal, D. Muthná, V. Řeháček, M. Řezáčová, J. Marek, A. Tichý, R. Havelek
Status neindexováno Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
NLK
PubMed Central
od 2020 do Před 1 rokem
ROAD: Directory of Open Access Scholarly Resources
od 2020
PubMed
39149108
DOI
10.1039/d4md00311j
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
The increasing threat of nuclear incidents and the widespread use of ionizing radiation (IR) in medical treatments underscore the urgent need for effective radiation countermeasures. Despite the availability of compounds such as amifostine, their clinical utility is significantly limited by adverse side effects and logistical challenges in administration. This study focuses on the synthesis and evaluation of novel piperazine derivatives as potential radioprotective agents, with the aim of overcoming the limitations associated with current countermeasures. We designed, synthesized, and evaluated a series of 1-(2-hydroxyethyl)piperazine derivatives. The compounds were assessed for cytotoxicity across a panel of human cell lines, and for their radioprotective effects in the MOLT-4 lymphoblastic leukemia cell line and in peripheral blood mononuclear cells (PBMCs) exposed to gamma radiation. The radioprotective efficacy was further quantified using the dicentric chromosome assay (DCA) to measure DNA damage mitigation. Among the synthesized derivatives, compound 6 demonstrated the most significant radioprotective effects in vitro, with minimal cytotoxicity across the tested cell lines. Compound 3 also showed notable efficacy, particularly in reducing dicentric chromosomes, thus indicating its potential to mitigate DNA damage from IR. Both compounds exhibited superior safety profiles and effectiveness compared to amifostine, suggesting their potential as more viable radioprotective agents. This study highlights the development of novel piperazine derivatives with promising radioprotective properties. Compound 6 emerged as the leading candidate, offering an optimal balance between efficacy and safety, with compound 3 also displaying significant potential. These findings support the further development and clinical evaluation of these compounds as safer, and more effective radiation countermeasures.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24018032
- 003
- CZ-PrNML
- 005
- 20241016081811.0
- 007
- ta
- 008
- 241008s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1039/d4md00311j $2 doi
- 035 __
- $a (PubMed)39149108
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Chmil, Vojtěch $u Department of Radiobiology, Military Faculty of Medicine, University of Defence in Brno Trebesska 1575 500 05 Hradec Kralove Czech Republic $1 https://orcid.org/0000000235429080
- 245 10
- $a Second-generation piperazine derivatives as promising radiation countermeasures / $c V. Chmil, N. Živná, M. Milanová, A. Filipová, J. Pejchal, L. Prchal, D. Muthná, V. Řeháček, M. Řezáčová, J. Marek, A. Tichý, R. Havelek
- 520 9_
- $a The increasing threat of nuclear incidents and the widespread use of ionizing radiation (IR) in medical treatments underscore the urgent need for effective radiation countermeasures. Despite the availability of compounds such as amifostine, their clinical utility is significantly limited by adverse side effects and logistical challenges in administration. This study focuses on the synthesis and evaluation of novel piperazine derivatives as potential radioprotective agents, with the aim of overcoming the limitations associated with current countermeasures. We designed, synthesized, and evaluated a series of 1-(2-hydroxyethyl)piperazine derivatives. The compounds were assessed for cytotoxicity across a panel of human cell lines, and for their radioprotective effects in the MOLT-4 lymphoblastic leukemia cell line and in peripheral blood mononuclear cells (PBMCs) exposed to gamma radiation. The radioprotective efficacy was further quantified using the dicentric chromosome assay (DCA) to measure DNA damage mitigation. Among the synthesized derivatives, compound 6 demonstrated the most significant radioprotective effects in vitro, with minimal cytotoxicity across the tested cell lines. Compound 3 also showed notable efficacy, particularly in reducing dicentric chromosomes, thus indicating its potential to mitigate DNA damage from IR. Both compounds exhibited superior safety profiles and effectiveness compared to amifostine, suggesting their potential as more viable radioprotective agents. This study highlights the development of novel piperazine derivatives with promising radioprotective properties. Compound 6 emerged as the leading candidate, offering an optimal balance between efficacy and safety, with compound 3 also displaying significant potential. These findings support the further development and clinical evaluation of these compounds as safer, and more effective radiation countermeasures.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Živná, Natálie $u Department of Toxicology and Military Pharmacy, Military Faculty of Medicine, University of Defence in Brno Trebesska 1575 500 05 Hradec Kralove Czech Republic $u Biomedical Research Centre, University Hospital Hradec Kralove Sokolska 581 500 05 Hradec Kralove Czech Republic
- 700 1_
- $a Milanová, Marcela $u Department of Radiobiology, Military Faculty of Medicine, University of Defence in Brno Trebesska 1575 500 05 Hradec Kralove Czech Republic $1 https://orcid.org/0000000223396197 $7 xx0252799
- 700 1_
- $a Filipová, Alžběta $u Department of Radiobiology, Military Faculty of Medicine, University of Defence in Brno Trebesska 1575 500 05 Hradec Kralove Czech Republic $1 https://orcid.org/0000000238496449 $7 ola2018976993
- 700 1_
- $a Pejchal, Jaroslav $u Department of Toxicology and Military Pharmacy, Military Faculty of Medicine, University of Defence in Brno Trebesska 1575 500 05 Hradec Kralove Czech Republic
- 700 1_
- $a Prchal, Lukáš $u Biomedical Research Centre, University Hospital Hradec Kralove Sokolska 581 500 05 Hradec Kralove Czech Republic
- 700 1_
- $a Muthná, Darina $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University Simkova 870 500 03 Hradec Kralove Czech Republic havelekr@lfhk.cuni.cz
- 700 1_
- $a Řeháček, Vít $u Transfusion Department, University Hospital Hradec Kralove Sokolska 581 500 05 Hradec Kralove - Novy Hradec Kralove Czech Republic
- 700 1_
- $a Řezáčová, Martina $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University Simkova 870 500 03 Hradec Kralove Czech Republic havelekr@lfhk.cuni.cz $1 https://orcid.org/0000000153702290 $7 nlk20020124956
- 700 1_
- $a Marek, Jan $u Biomedical Research Centre, University Hospital Hradec Kralove Sokolska 581 500 05 Hradec Kralove Czech Republic $u Department of Epidemiology, Military Faculty of Medicine, University of Defence in Brno Trebesska 1575 500 05 Hradec Kralove Czech Republic
- 700 1_
- $a Tichý, Aleš $u Department of Radiobiology, Military Faculty of Medicine, University of Defence in Brno Trebesska 1575 500 05 Hradec Kralove Czech Republic $u Biomedical Research Centre, University Hospital Hradec Kralove Sokolska 581 500 05 Hradec Kralove Czech Republic $1 https://orcid.org/0000000282625703 $7 xx0135624
- 700 1_
- $a Havelek, Radim $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University Simkova 870 500 03 Hradec Kralove Czech Republic havelekr@lfhk.cuni.cz $1 https://orcid.org/0000000305281334 $7 xx0230947
- 773 0_
- $w MED00208004 $t RSC medicinal chemistry $x 2632-8682 $g Roč. 15, č. 8 (2024), s. 2855-2866
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39149108 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241008 $b ABA008
- 991 __
- $a 20241016081807 $b ABA008
- 999 __
- $a ok $b bmc $g 2196440 $s 1229983
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 15 $c 8 $d 2855-2866 $e 20240711 $i 2632-8682 $m RSC medicinal chemistry $n RSC Med Chem $x MED00208004
- LZP __
- $a Pubmed-20241008